Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Rating of “Hold” from Analysts

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have received a consensus recommendation of “Hold” from the thirteen brokerages that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $19.70.

AARD has been the subject of several recent analyst reports. Weiss Ratings raised Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. BTIG Research downgraded shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. B. Riley Financial dropped their target price on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, Morgan Stanley reissued an “underweight” rating and issued a $3.00 price target (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th.

Aardvark Therapeutics Stock Performance

Shares of AARD stock opened at $6.26 on Friday. Aardvark Therapeutics has a 52-week low of $3.35 and a 52-week high of $17.94. The company has a market capitalization of $136.97 million, a PE ratio of -1.95 and a beta of 3.93. The business’s fifty day moving average is $4.78 and its 200 day moving average is $7.68.

Aardvark Therapeutics (NASDAQ:AARD) last posted its earnings results on Thursday, May 7th. The company reported ($0.99) EPS for the quarter. On average, sell-side analysts forecast that Aardvark Therapeutics will post -3.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Aardvark Therapeutics during the second quarter worth about $42,000. China Universal Asset Management Co. Ltd. bought a new stake in Aardvark Therapeutics in the 4th quarter worth approximately $47,000. Persistent Asset Partners Ltd bought a new stake in Aardvark Therapeutics in the 4th quarter worth approximately $56,000. New York State Common Retirement Fund purchased a new stake in Aardvark Therapeutics in the second quarter worth approximately $99,000. Finally, MetLife Investment Management LLC purchased a new stake in Aardvark Therapeutics in the fourth quarter worth approximately $102,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.